Anavex Life Sciences - Stock price, News & Analysis

AVXL fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

AVXL Stock Overview

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases.

Rewards

Earnings are forecast to grow 54.95% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been diluted in the past year

Price History & Performance

Summary of all time highs, changes and price drops for Anavex Life Sciences
Historical stock prices
Current Share Price	US$14.39
52 Week High	US$31.50
52 Week Low	US$5.56
Beta	0.57
1 Month Change	-20.67%
3 Month Change	-20.06%
1 Year Change	147.25%
3 Year Change	690.66%
5 Year Change	242.62%
Change since IPO	21,484.57%

Recent News & Updates

Jan 17

Anavex: 2022 Has Major, Pivotal Catalysts

Anavex's long story is coming to a climax this year. The company will announce topline data from the Alzheimer's trial by 2H 2022. This will be the most important event in the lifecycle of this company.

Nov 16

Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Anavex Life...

Nov 05

Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?

Cassava Sciences' Simufilam is now seen as the best hope to treat all patients in Alzheimer's disease after disappointment in Cortexyme's data. Cortexyme failed to prevent disease progression in 50% of patients on what was hopefully an upstream mechanism of action vs. Simufilam. The CTAD Conference in November will shed much light on the most recent clinical data of Anavex, Cassava Sciences and Cortexyme. The future of Alzheimer's treatments will probably consist of a combination of treatments to maximize results as in oncology. On November 4, 2021, Cassava Sciences announced no wrongdoing was found by the American Journal of Neuroscience on its data.

Shareholder Returns

	AVXL	US Biotechs	US Market
7D	-7.0%	-1.2%	-0.5%
1Y	147.3%	-14.3%	13.7%

Return vs Industry: AVXL exceeded the US Biotechs industry which returned -14.3% over the past year.

Return vs Market: AVXL exceeded the US Market which returned 13.7% over the past year.

Price Volatility

Is AVXL's price volatile compared to industry and market?
AVXL volatility
AVXL Average Weekly Movement	9.1%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.6%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	2.4%

Stable Share Price: AVXL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: AVXL's weekly volatility has decreased from 15% to 9% over the past year.

About the Company

Founded	Employees	CEO	Website
2004	25	Chris Missling	https://www.anavex.com

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer’s disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson’s disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company’s drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases.

Anavex Life Sciences Fundamentals Summary

How do Anavex Life Sciences's earnings and revenue compare to its market cap?
AVXL fundamental statistics
Market Cap	US$1.09b
Earnings (TTM)	-US$37.91m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-28.9x

P/E Ratio

Is AVXL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
AVXL income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Expenses	US$37.91m
Earnings	-US$37.91m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.50
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did AVXL perform over the long term?

See historical performance and comparison

Valuation

Is Anavex Life Sciences undervalued compared to its fair value and its price relative to the market?

7.25x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AVXL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AVXL's fair value to establish if it is undervalued.

Price To Earnings Ratio

PE vs Industry: AVXL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AVXL is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AVXL's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: AVXL is overvalued based on its PB Ratio (7.3x) compared to the US Biotechs industry average (2.2x).

Future Growth

How is Anavex Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

55.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVXL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: AVXL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AVXL's is expected to become profitable in the next 3 years.

Revenue vs Market: AVXL is forecast to have no revenue next year.

High Growth Revenue: AVXL is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AVXL's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Anavex Life Sciences performed over the past 5 years?

-19.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AVXL is currently unprofitable.

Growing Profit Margin: AVXL is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: AVXL is unprofitable, and losses have increased over the past 5 years at a rate of 19.5% per year.

Accelerating Growth: Unable to compare AVXL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AVXL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).

Return on Equity

High ROE: AVXL has a negative Return on Equity (-25.14%), as it is currently unprofitable.

Financial Health

How is Anavex Life Sciences's financial position?

Financial Position Analysis

Short Term Liabilities: AVXL's short term assets ($161.6M) exceed its short term liabilities ($10.8M).

Long Term Liabilities: AVXL has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: AVXL is debt free.

Reducing Debt: AVXL had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AVXL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: AVXL has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 25.6% each year

Dividend

What is Anavex Life Sciences's current dividend yield, its reliability and sustainability?

Dividend Yield vs Market

Notable Dividend: Unable to evaluate AVXL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AVXL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AVXL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AVXL's dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AVXL's dividend in 3 years as they are not forecast to pay a notable one for the US market.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average management tenure

CEO

Chris Missling (55 yo)

8.5yrs

Tenure

US$9,417,057

Compensation

Dr. Christopher U. Missling, also known as the Chris, MS, Ph D., MBA, has been the Chief Executive Officer and President at Anavex Life Sciences Corp. since July 05, 2013 and had been its Chief Financial O...

CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD9.42M) is above average for companies of similar size in the US market ($USD2.31M).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: AVXL's management team is seasoned and experienced (5 years average tenure).

Board Members

Experienced Board: AVXL's board of directors are considered experienced (8.1 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.5%.

Data	Last Updated (UTC time)
Company Analysis	2022/01/17 23:16
End of Day Share Price	2022/01/14 00:00
Earnings	2021/09/30
Annual Earnings	2021/09/30